Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo

Neuroscience

Volumn 91, Issue 2, 1999, Pages 599-606

  Willins, D L ^a   Berry, S A ^a   Alsayegh, L ^a   Backstrom, J R ^b   Sanders Bush, E ^b   Friedman, L ^a   Roth, B L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotic; Internalization; Olanzapine; Serotonin; Trafficking

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLORGYLINE; CLOZAPINE; HALOPERIDOL; MIANSERIN; OLANZAPINE; PRAZOSIN; QUIPAZINE; RISPERIDONE; RITANSERIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; ZIMELDINE;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN 3T3; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DENDRITE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; FIBROBLAST; IMMUNOREACTIVITY; INTERNALIZATION; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PYRAMIDAL NERVE CELL; RAT; RECEPTOR BLOCKING;

3T3 CELLS; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL LINE; CLOZAPINE; DENDRITES; FLUOROBENZENES; HALOPERIDOL; MIANSERIN; MICE; PIPERIDINES; PIRENZEPINE; PREFRONTAL CORTEX; PYRAMIDAL CELLS; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; RISPERIDONE; RITANSERIN; SEROTONIN ANTAGONISTS; TRANSFECTION;

EID: 0032907534     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(98)00653-8     Document Type: Article

References (29)

1. Aghajanian G.K., Marek G.J. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology. 36:1997;589-599.
2. Attramadal H., Arriza J.L., Aoki C., Dawson T.M., Codina J., Kwatra M.M., Snyder S.H., Caron M.G., Lefkowitz R.J. Beta-Arrestin 2, a novel member of the Arrestin/Beta-Arrestin gene family. J. biol. Chem. 267:1992;17,882-17,890.
3. Backstrom J.R., Sanders-Bush E. Generation of anti-peptide antibodies against serotonin 5-HT2A and 5-HT2C receptors. J. Neurosci. Meth. 77:1997;109-117.
4. Berry S., Shah M., Khan N., Roth B. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Molec. Pharmac. 50:1996;306-313.
5. Berry S., Shah M., Khan N., Roth B. Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Molec. Pharmac. 50:1996;306-313.
6. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmac. exp. Ther. 260:1992;576-580.
7. Duinkerke S.J., Botter P.A., Jansen A.A.I., Van Dongen P.A.M., Van Haaften A.J., Boom A.J., van Laarhoven J.H., Busard H.L. Ritanserin, a selective 5-HT2c/1c antagonist, and negative symptoms in schizophrenia: a placebo-controlled double-blind trial. Br. J. Psychiat. 163:1993;451-455.
8. Ferguson S., Barak L., Zhang J., Caron M. G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins. Can. J. Physiol. Pharmac. 74:1996;1095-1110.
9. Glennon R.A., Titler M., McKenney J.D. Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sci. 35:1984;2505-2511.
10. Jakab R., Goldman-Rakic P. 5-Hydroxytryptamine2A serotonin receptors in the primate cerebral cortex: possible site of action of hallucinogenic and antipsychotic drugs in pyramidal cell apical dendrites. Proc. natn. Acad. Sci. U.S.A. 95:1998;735-740.
11. Kehne J.H., Baron B.M., Carr A.A., Chaney S.F., Elands J., Feldman D.J., Frank R.A., van Giersbergen P.L., McCloskey T.C., Johnson M.P., McCarty D.R., Poirot M., Senyah Y., Siegel B.W., Widmaier C. Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J. Pharmac. exp. Ther. 277:1996;968-981.
12. Meltzer H., Cola P. The pharmacoeconomics of clozapine: a review. J. clin. Psychiat. 55(Suppl. B):1994;161-165.
13. Meltzer H. Y. (1989) Clozapine: clinical advantages and biological mechanisms. In Schizophrenia: A Scientific Focus (eds Schulz S. C. and Tamminga C.), pp. 302-309. Oxford University Press, New York.
14. i values. J. Pharmac. exp. Ther. 251:1989;238-246.
15. Mizuki Y., Kajimura N., Imai T., Suetsugi M., Kai S., Kaneyuki H., Yamada M. Effects of mianserin on negative symptoms in schizophrenia. Int. clin. Psychopharmac. 5:1990;83-95.
16. Pazos A., Cortes R., Palacios J.M. Quantitative autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res. 346:1985;231-249.
17. Roth B.L., Ciaranello R., Meltzer H. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J. Pharmac. exp. Ther. 260:1992;1361-1365.
18. Roth B.L., Palvimaki E.P., Berry S.A., Khan N., Sachs N., Uluer A., Choudhary M.S. 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J. Pharmac. exp. Ther. 275:1995;1638-1646.
19. Roth B. L. and Meltzer H. (1995) The role of serotonin in schizophnrenia. In Psychopharmacology: The Fourth Generation of Progress (eds Bloom F. and Kupfer D.), pp. 1215-1227. Raven, New York.
20. Roth B. L., Meltzer H. and Khan N. (1998) Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. In Advances in Pharmacology (eds Goldstein D. S., Eisenhoffer G. and McCarty R.), Vol. 42, pp. 482-485. Academic, San Diego.
21. Roth B.L., Ciaranello R.D., Meltzer H.Y. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J. Pharmac. exp. Ther. 260:1992;1361-1365.
22. Roth B.L., Craigo S.C., Choudhary M.S., Uluer A., Monsma F.J. Jr., Shen Y., Meltzer H.Y., Sibley D.R. Binding of typical and atypical antipsychotic agents to 5- hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmac. exp. Ther. 268:1994;1403-1410.
23. 3H]ketanserin recognition sites in rat striatum. J. Neurochem. 49:1987;1833-1838.
24. Roth B.L., Tandra S., Burgess L.H., Sibley D.R., Meltzer H.Y. D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology, Berlin. 120:1995;365-368.
25. Schwindt P., Crill W. Local and propagated dendritic action potentials evoked by glutamate iontophoresis on rat neocortical pyramidal neurons. J. Neurophysiol. 78:1997;187-198.
26. Sorensen S.M., Kehne J.H., Fadayl E.M., Humphreys T.M., Ketteler H.J., Sullivan C., Taylor V.L., Schmidt C.J. Characterization of the 5-HT2 antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies. J. Pharmac. exp. Ther. 266:1993;684-691.
27. Wiesel F.A., Nordstrom A.L., Farde L., Eriksson B. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology, Berlin. 114:1994;31-38.
28. Willins D., Deutch A., Roth B. Serotonin 5-HT2A receptors are expressed on pyramidal cells and interneurons in the rat cortex. Synapse. 27:1997;79-82.
29. Yuste R., Tank D. Dendritic integration in mammalian neurons, a century after Cajal. Neuron. 16:1996;701-716.